Funder
European Research Council
Krebsliga Schweiz
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Reference119 articles.
1. Minimal residual disease in solid neoplasia: new frontier or red-herring?;Mordant;Cancer Treat. Rev.,2012
2. Minimal residual disease in cancer therapy – small things make all the difference;Blatter;Drug Resist. Updat.,2015
3. Emerging insights into targeted therapy-tolerant persister cells in cancer;Cabanos;Cancers,2021
4. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?;Borst;Open Biol.,2012
5. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells;Ramirez;Nat. Commun.,2016